Back to results
US 2022/0291232 A1Published application
Assays for determining plasma kallikrein system biomarkers
AssigneeTakeda Pharmaceutical Company Limited
InventorsDaniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman
Life of this patent
Estimating the term…
Abstract
Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.
Claims16
-13. (canceled)
A method for assessing plasma activation, comprising:
- providing a plasma sample from a subject;
- and
- measuring the level of cleaved high molecular weight kininogen (HMWK) in the plasma sample.
-41. (canceled)
Dependencies are inferred from the claim text.